This article is more than 5 years old. Information may no longer be current.

B&L granted marketing approval for brimonidine 0.2%

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bausch & Lomb announced yesterday it was granted U.S. marketing approval for brimonidine 0.2% for use in lowering intraocular pressure in people with open-angle glaucoma or ocular hypertension.

Brimonidine 0.2% was sold by Allergan under the brand name Alphagan. Allergan took the product off the market when it introduced Alphagan P, a lower dose version of brimonidine. According to Allergan, Alphagan showed higher rates of some adverse events, such as ocular allergy, than the lower-dosed version.

According to a Bausch & Lomb news release, its version of brimonidine is available immediately.

Allergan had pursued patent litigation against Bausch & Lomb over the drug, but ultimately lost those suits. Meanwhile, Allergan’s own generic division plans to introduce its own version of brimonidine 0.2%.